197 related articles for article (PubMed ID: 16634913)
1. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
[No Abstract] [Full Text] [Related]
2. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
[No Abstract] [Full Text] [Related]
3. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
Humbert M; Cabane J
Rheumatology (Oxford); 2003 Jan; 42(1):191-3. PubMed ID: 12509640
[No Abstract] [Full Text] [Related]
5. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
[No Abstract] [Full Text] [Related]
6. Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma.
Ferreira ME; Scheinberg MA
Ann Rheum Dis; 2008 Dec; 67(12):1784-5. PubMed ID: 19005155
[No Abstract] [Full Text] [Related]
7. Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers.
Catarsi E; Doveri M; Tavoni A
Reumatismo; 2013 May; 65(2):79-81. PubMed ID: 23877412
[TBL] [Abstract][Full Text] [Related]
8. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
[TBL] [Abstract][Full Text] [Related]
9. Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis.
Lambova S; Müller-Ladner U
Nat Rev Rheumatol; 2011 Jan; 7(1):5-6. PubMed ID: 21119606
[No Abstract] [Full Text] [Related]
10. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
[TBL] [Abstract][Full Text] [Related]
11. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon.
Moore TL; Vail A; Herrick AL
Rheumatology (Oxford); 2007 Feb; 46(2):363-4. PubMed ID: 17116656
[No Abstract] [Full Text] [Related]
12. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
Hamaguchi Y; Sumida T; Kawaguchi Y; Ihn H; Tanaka S; Asano Y; Motegi SI; Kuwana M; Endo H; Takehara K
J Dermatol; 2017 Jan; 44(1):13-17. PubMed ID: 27374274
[TBL] [Abstract][Full Text] [Related]
13. Resolution of severe digital ulceration during a course of Bosentan therapy.
Snyder MJ; Jacobs MR; Grau RG; Wilkes DS; Knox KS
Ann Intern Med; 2005 May; 142(9):802-3. PubMed ID: 15867420
[No Abstract] [Full Text] [Related]
14. Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers.
Hafner F; Thomas G; Froehlich H; Steidl K; Brodmann M
Int Angiol; 2011 Oct; 30(5):493-5. PubMed ID: 21804491
[No Abstract] [Full Text] [Related]
15. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis.
Dhillon S
Drugs; 2009 Oct; 69(14):2005-24. PubMed ID: 19747014
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.
Moinzadeh P; Hunzelmann N; Krieg T
J Am Acad Dermatol; 2011 Sep; 65(3):e102-e104. PubMed ID: 21839301
[No Abstract] [Full Text] [Related]
17. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
Gholam P; Sehr T; Enk A; Hartmann M
Dermatology; 2009; 219(2):171-3. PubMed ID: 19590168
[TBL] [Abstract][Full Text] [Related]
18. Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
Kurgyis Z; Varga R; Sick I; Lang MU; Ruzicka T; Sárdy M
Acta Derm Venereol; 2011 Oct; 91(6):716-7. PubMed ID: 21879251
[No Abstract] [Full Text] [Related]
19. [Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)].
Riccardi MT; Chialà A; Lannone F; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2007; 59(2):135-9. PubMed ID: 17603693
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of bosentan in digital ischemic ulcers.
Todoli Parra JA; Hernández MM; Arrébola López MA
Ann Vasc Surg; 2010 Jul; 24(5):690.e1-4. PubMed ID: 20579585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
